Meeting
2024 ASCO Genitourinary Cancers Symposium
MAPK pathway alterations as a targetable vulnerability in bladder cancer.
Authors
Vincent D'Andrea
Brigham and Women's Hospital, Boston, MA
Vincent D'Andrea , Raie Bekele , Timothy Hanlon , Yuzhen Zhou , Rea Chroneos , Isabella Stelter , Kent William Mouw
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Translational Research, Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 672)
DOI
10.1200/JCO.2024.42.4_suppl.672
Abstract #
672
Poster Bd #
K16
Abstract Disclosures
Similar Posters
Poster
2016 Gastrointestinal Cancers Symposium
Adding targeted inhibition of PI3K and MAPK signaling pathways to standard chemotherapy in experimental pancreatic cancer.
First Author: Niranjan Awasthi
Poster
2024 ASCO Annual Meeting
PAS-004: A novel macrocyclic MEK inhibitor to inhibit cancer cell growth in vitro and tumor growth in mouse xenograft studies.
First Author: Graeme Currie
Poster
2021 ASCO Annual Meeting
Molecular characterization of the Ras-MAPK pathway in metastatic breast cancer.
First Author: Justin Wayne Wong Tiu-lim
First Author: Nuala McCabe